RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 Lenvatinib Improves Progression-Free Survival in Refractory Thyroid Cancer
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 14
SP 13
OP 14
DO 10.1177/155989771414005
UL http://mdc.sagepub.com/content/14/14/13.abstract
AB This article presents outcomes from A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (SELECT; NCT01321554) [Schlumberger M et al. J Clin Oncol 2014]. The trial compared the progression-free survival (of subjects with 131I-refractory differentiated thyroid cancer who were treated with lenvatinib versus placebo.